There are currently 25 active clinical trials seeking participants for Non-Alcoholic Fatty Liver Disease research studies. The states with the highest number of trials for Non-Alcoholic Fatty Liver Disease participants are Texas, California, Florida and Arizona.
Human Models of Selective Insulin Resistance: Alpelisib, Part I
NCT06354088
Recruiting
The goal of this clinical trial is to understand how the blood sugar-lowering hormone insulin works in healthy adults versus those who are at risk for type 2 diabetes. The study will use a drug called alpelisib, which interferes with insulin's actions in the body, to answer the study's main question: does the liver continue to respond to insulin's stimulation of fat production even when it loses the ability to stop making glucose (sugar) in response to insulin. Researchers will compare the impac... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/11/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Insulin Resistance, Prediabetic State, Overweight and Obesity, Non-Alcoholic Fatty Liver Disease
Register for Updates
Endoscopic Ultrasound Shear Wave Elastography in Patients With Non-alcoholic Fatty Liver Disease
NCT05728697
Recruiting
The goal of this observation study is to assess whether endoscopic ultrasound shear wave elastography (EUS-SWE) may be a useful tool for liver fibrosis screening in patients with elevated body mass index and non alcoholic fatty liver disease as compared to other non-invasive screening modalities, which have traditionally had less accurate results in this population. The main questions it aims to answer are: * Determine accuracy of EUS-SWE for liver fibrosis screening compared to other non-inva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/05/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Non-Alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis, Obesity
Register for Updates
Glycemic Effect of Diazoxide in NAFLD
NCT05729282
Recruiting
The goal of this clinical trial is to compare a two-week course of diazoxide (at two different doses) and placebo in people with overweight/obesity and insulin resistance (IR) with, or at high risk for, non-alcoholic fatty liver disease (NAFLD). The main questions it aims to answer are how mitigation of compensatory hyperinsulinemia with diazoxide affects parameters of glucose and lipid metabolism (how people with IR and NAFLD respond to lowering high insulin levels so that the investigators can... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/06/2025
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
Register for Updates
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
NCT05464784
Recruiting
The design of the Phase 2 clinical trial includes the following elements: * Multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate MN-001 (tipelukast) vs. placebo in approximately 40 patients in the U.S. * Patients will be randomized 1:1 to receive either 500 mg/day of MN-001 (tipelukast) or placebo for 24 weeks. * The co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (CAP) score at Week 24, and (2)... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
11/18/2024
Locations: Jubilee Clinical Research, Inc., Las Vegas, Nevada
Conditions: Diabetes Mellitus, Type 2, Hypertriglyceridemia, Non-Alcoholic Fatty Liver Disease
Register for Updates
Quantifying Hepatic Mitochondrial Fluxes in Humans
NCT05305287
Recruiting
In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/29/2024
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Non-Alcoholic Fatty Liver Disease, Type 2 Diabetes, Mitochondrial Metabolism Disorders
Register for Updates
Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)
NCT06571474
Recruiting
The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals. Both groups will have: * screening visit * imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \[MRI\] and... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/22/2024
Locations: University of Missouri School of Medicine, Columbia, Missouri
Conditions: Obesity, Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Healthy
Register for Updates
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
NCT06133101
Recruiting
A randomized, controlled study of standard soy milk consumption compared to 2% fat cow's milk consumption in children with Non-alcoholic Fatty Liver Disease (NAFLD). The investigators hypothesize that the daily consumption of soy isoflavones found in the soy milk will be beneficial in reducing NAFLD and other obesity-related comorbidities. The investigators do not expect any adverse endocrine or metabolomic effects from the consumption of soy isoflavones.
Gender:
ALL
Ages:
Between 5 years and 12 years
Trial Updated:
08/19/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT05463796
Recruiting
This research study is creating a way to collect and store specimens and information from participants who may be at an increased risk of developing cancer, or has been diagnosed with an early phase of a cancer or a family member who has a family member with a precursor condition for cancer. * The objective of this study is to identify exposures as well as clinical, molecular, and pathological changes that can be used to predict early development of cancer, malignant transformation, and risks o... Read More
Gender:
ALL
Ages:
All
Trial Updated:
07/30/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Cancer Risk, Cancer Predisposition Syndrome, Hereditary Cancer Prediction, Childhood Cancer Survivors, Adult Cancer Survivors, IARC Carcinogens, Smoking History, Lung Cancer, Ductal/Lobular Carcinoma, Barrett Esophagus, Pancreatic Precursor Lesions, Colonic Dysplasia/Adenomata, Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, Cirrhosis, High Grade Prostatic Epithelial Neoplasia, High-grade Bladder Urothelial Dysplasia/Carcinoma in Situ, Adenomatous Hyperplasia, High-risk Oral Precancerous Diseases, Melanocytic Lesion, Adult, Hematologic Malignancy, Lung; Node, Serous Tubal Intraepithelial Carcinoma, Endometrial Intraepithelial Neoplasia, Cervical and Endocervical Carcinoma in Situ, Vulvar Intraepithelial Neoplasia, Nephrogenic Rests, Benign Bone Lesions With Risk of Malignant Degeneration, Giant Cell Tumor, Osteochondroma, Spitz Nevus
Register for Updates
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
NCT03073343
Recruiting
Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/06/2024
Locations: VA Long Beach Healthcare System, Long Beach, California
Conditions: Non-Alcoholic Fatty Liver Disease, Non Insulin Dependent Diabetes, ALT
Register for Updates
Intermittent Fasting for NAFLD in Adults
NCT04899102
Recruiting
NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\<30kg/m2) is an increasingly recognized condition, sometimes described as "lean NAFLD". Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Fatty Liver, Intermittent Fasting, Fatty Liver, Nonalcoholic, Non-Alcoholic Fatty Liver Disease, Liver Fat
Register for Updates
Hyperpolarized Pyruvate (13C) Magnetic Resonance Imaging In Patients With Fatty Liver Disease
NCT06176079
Recruiting
The recent development of dissolution dynamic nuclear polarization (DNP) technology for hyperpolarized (HP) 13C imaging offers a promising new avenue for non-invasively accessing fundamental metabolic changes associated with the progression of fatty liver disease in vivo. The purpose of this pilot study is to optimize sequence parameters for hyperpolarized 13C acquisition in the human liver and determine which metabolic changes can be seen in humans with simple, non-alcoholic fatty liver disease... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/10/2023
Locations: University of California, San Francisco, San Francisco, California
Conditions: Non-Alcoholic Fatty Liver Disease, Non Alcoholic Fatty Liver, Non Alcoholic Steatohepatitis, NAFLD, NASH
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Central Research Associates, Birmingham, Alabama +73 locations
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates